Robert Lisicki, insider at Arena Pharmaceuticals

Robert Lisicki Insider Information

Robert Lisicki has served as our Executive Vice President and Chief Commercial Officer since November 2018. Prior to joining Arena, Mr. Lisicki most recently served as General Manager, Vice President Cardio-Metabolic and Inflammation at Regeneron Pharmaceuticals, Inc. Prior to joining Regeneron, he was Senior Vice President of Sales and Marketing and Chief Customer Officer at Daiichi Sankyo, Inc. Prior to his time at Daiichi Sankyo, Mr. Lisicki held several management positions at Amgen, including Vice President and General Manager, responsible for a 700-plus-person sales force in the United States. His US leadership experiences consisted of working with such market-shaping products as Enbrel and Prolia. During his tenure, he also covered several ex-US regions and worked as an International Franchise Lead running the development and international strategies and business plans across Amgen’s portfolio, including Nephrology, Cardiology, Bone, and Oncology. Prior to joining Amgen, Mr. Lisicki held various sales and marketing positions at Johnson & Johnson. Mr. Lisicki brings over 20 years of experience in biopharmaceutical management, sales, and marketing to Arena. Mr. Lisicki holds a BS in finance and business administration from the State University of New York at Albany.

What is Robert Lisicki's net worth?

The estimated net worth of Robert Lisicki is at least $3.36 million as of August 3rd, 2021. Mr. Lisicki owns 33,601 shares of Arena Pharmaceuticals stock worth more than $3,359,764 as of August 17th. This net worth evaluation does not reflect any other assets that Mr. Lisicki may own. Additionally, Mr. Lisicki receives a salary of $686,630.00 as EVP at Arena Pharmaceuticals. Learn More about Robert Lisicki's net worth.

How old is Robert Lisicki?

Mr. Lisicki is currently 54 years old. There are 1 older executives and no younger executives at Arena Pharmaceuticals. The oldest executive at Arena Pharmaceuticals is Mr. Michael E. Paolucci, Exec. VP of HR, who is 62 years old. Learn More on Robert Lisicki's age.

What is Robert Lisicki's salary?

As the EVP of Arena Pharmaceuticals, Inc., Mr. Lisicki earned a total compensation package of $2,158,332.00 in 2020. Mr. Lisicki earned a salary of $428,450.00, a bonus of $10,804.00, options awards of $1,471,701.00, non-equity compensation of $229,034.00, and other compensation of $18,342.00.There are 2 executives that earn more than Mr. Lisicki. The highest earning executive at Arena Pharmaceuticals is Mr. Amit D. Munshi M.B.A., Pres & CEO, who commands a salary of $1,220,000.00 per year. Learn More on Robert Lisicki's salary.

How do I contact Robert Lisicki?

The corporate mailing address for Mr. Lisicki and other Arena Pharmaceuticals executives is 6154 Nancy Ridge Drive, San Diego CA, 92121. Arena Pharmaceuticals can also be reached via phone at (858) 453-7200 and via email at [email protected] Learn More on Robert Lisicki's contact information.

Has Robert Lisicki been buying or selling shares of Arena Pharmaceuticals?

Robert Lisicki has not been actively trading shares of Arena Pharmaceuticals in the last ninety days. Most recently, Robert Lisicki sold 17,500 shares of the business's stock in a transaction on Tuesday, August 3rd. The shares were sold at an average price of $60.08, for a transaction totalling $1,051,400.00. Following the completion of the sale, the executive vice president now directly owns 33,601 shares of the company's stock, valued at $2,018,748.08. Learn More on Robert Lisicki's trading history.

Who are Arena Pharmaceuticals' active insiders?

Arena Pharmaceuticals' insider roster includes Vincent Aurentz (VP), Christopher Cabell (CMO), Jayson Dallas (Director), Robert Lisicki (EVP), Amit Munshi (CEO), Tina Nova (Director), Manmeet Soni (Director), and Manmeet Soni (Director). Learn More on Arena Pharmaceuticals' active insiders.

Robert Lisicki Insider Trading History at Arena Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/3/2021Sell17,500$60.08$1,051,400.0033,601View SEC Filing Icon  
2/2/2021Sell17,500$78.87$1,380,225.0026,941View SEC Filing Icon  
8/4/2020Sell30,000$63.34$1,900,200.0030,000View SEC Filing Icon  
11/13/2019Sell4,429$45.83$202,981.07View SEC Filing Icon  
See Full Table

Robert Lisicki Buying and Selling Activity at Arena Pharmaceuticals

This chart shows Robert Lisicki's buying and selling at Arena Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Arena Pharmaceuticals Company Overview

Arena Pharmaceuticals logo
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Eisai Co., Ltd. and Eisai Inc.; Boehringer Ingelheim International GmbH; Beacon Discovery, Inc.; and Aristea Therapeutics, Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. As of March 11, 2022, Arena Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc.
Read More

Today's Range

Now: $99.99
Low: $99.99
High: $99.99

50 Day Range

MA: $97.65
Low: $93.13
High: $99.99

2 Week Range

Now: $99.99
Low: $45.50
High: $100.00

Volume

107 shs

Average Volume

1,561,326 shs

Market Capitalization

$6.17 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.55